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the 1950s in Sri Lanka and Guyana.
The reports of the Sri Lanka study are
not in the peer-reviewed literature.
Data from the Guyana sugar planta-
tions must include factors other than
DDT and malaria because profound
differences existed in all-cause mor-
tality in adults and children over the
span of the reports. Whether DDTwas
effective in those areas at that time
cannot determine whether it would be
a two-edged sword now. 
Although the p,p′ isomer of DDE
is in human tissue at the highest con-
centration, technical DDT contains
approximately 10% of the o,p isomer,
and o,p-DDE can be detected if
sought (4). We and others measure
p,p′-DDE as an index of total DDE,
but our hypothesis for the estrogenic
mechanism by which lactation time
might be shortened involves the estro-
genic isomer p,p'-DDE. The
Kornbrust study of DDE and lactation
in rodents used pure p, p-DDE, the
most prevalent congener but also the
least estrogenic one (5). Since the
hypothesis concerned o,p-DDE, the
estrogenic congener, the work was
unfortunately noncontributory.
Malaria is a major public health
problem, and vigorous efforts to pre-
vent and treat it are necessary. We
fear, though, that DDT is not entirely
benign and have some evidence to
show this. Proceeding as if the safety
of DDT had been demonstrated
absolutely does not seem a prudent
course. DDT is inexpensive; however,
cost is irrelevant if DDT use causes as
many infant deaths as it prevents.
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To the Editor: In gram-negative
bacteria, β-lactamases are an impor-
tant cause of antimicrobial resistance.
In the 1990s, several new β-lacta-
mases, including CTX-M type and
plasmid-mediated AmpC β-lacta-
mases, emerged.
CTX-M extended spectrum β-lac-
tamases (ESBLs) differ from those
derived from TEM and SHV enzymes
by their preferential hydrolysis of
cefotaxime and ceftriaxone compared
with ceftazidime. They also differ
from an evolutionary standpoint and
are more closely related to the chro-
mosomal enzymes of Kluyvera
species (1). These enzymes are
increasingly described worldwide,
particularly in South America,
Europe, and East Asia.
AmpC enzymes confer resistance
to oxyimino- and 7-α-methoxy-
cephalosporins. They occur naturally
in the chromosomes of bacteria such
as Enterobacter, Citrobacter, Serratia,
and Pseudomonas species. In the last
decade, genes coding for AmpC β-lac-
tamases have made their way into
plasmids and are increasingly detected
in other species, notably Klebsiella
and Escherichia coli (2).
We describe five strains of
Enterobacteriaceae with unusual
antimicrobial susceptibility patterns,
which were isolated from patients in
an 800-bed hospital in Singapore. K.
pneumoniae EU17113, EU2673, and
E. coli EU2657 were noted to be more
susceptible to ceftazidime than ceftri-
axone, whereas E. coli EU4855 and
EB9505 were resistant to both
cephalosporins. The National
Committee for Clinical Laboratory
Standards ESBL confirmatory test (3)
was positive for strains EU17113,
EU2673, and EU2657 but negative
for strains EU4855 and EB9505. All
strains were isolated from urine cul-
tures except EB9505, which was iso-
lated from blood culture. The isolates
were identified by VITEK 2
(bioMérieux, Marcy l’Etoile, France)
or Microbact 12E/A (Medvet
Diagnostics, Thebarton, Australia). 
The MICs by Etest (AB Biodisk,
Solna, Sweden) and isoelectric points
of β-lactamases in crude extracts are
shown in the Table. Polymerase chain
reaction (PCR) for CTX-M genes was
performed on strains EU17113,
EU2673, and EU2657 by using
primers CTX-1 and CTX-2 as
described by Pai et al. (4). This yield-
ed an ≈780-bp product with DNA
extracts from strain EU17113 but not
the others. The sequence of this prod-
uct was identical to blaCTX-M-9 as found
in the GenBank database (accession
no. AJ416345.1). PCR was repeated
for strains EU2673 and EU2657 with a
different primer set as described by
Gniadkowski et al. (5). This produced
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≈600-bp products which were identi-
cal to blaCTX-M-11  and  blaCTX-M-15
(accession no. AJ310929.1 and
AY463958.1) for EU2673, and blaCTX-
M-2, blaCTX-M-20 and blaToho-1 (accession
no. X92507.1, AJ416344.1, and
D37830.1) for EU2657.
CTX-M ESBLs can be grouped
into four clusters based on the similar-
ity of their amino acid sequences:
CTX-M-1 type (CTX-M-1, -3, -10, -
11, -12, -15, -23, -28), CTX-M-2 type
(CTX-M-2, -4, -5, -6, -7, -20, Toho-
1), CTX-M-9 type (CTX-M-9, -13, -
14, -16, -17, -18, -19, -21, Toho-2),
and CTX-M-8. Three of the four clus-
ters of CTX-M-type enzymes are rep-
resented in our small sample of iso-
lates. The only other report of CTX-M
enzymes in Southeast Asia of which
we are aware describes CTX-M-14
and -17 in Vietnam (6).
Diagnostic laboratories may fail to
identify CTX-M–positive isolates as
ESBL producers if ceftazidime resist-
ance is used as the sole screening cri-
terion, which is unlikely in Singapore
because ceftriaxone is usually in the
first-line panel for antimicrobial sus-
ceptibility testing of Enterobacter-
iaceae. In addition, ESBL screening is
conducted in most laboratories by the
Jarlier double disk diffusion method
(7), with at least two different β-lac-
tam disks placed on either side of an
amoxicillin-clavulanate disk. How-
ever, CTX-M producers may not be
distinguished from other ESBL pro-
ducers because once the ESBL test is
positive, the organism is reported as
resistant to all third-generation
cephalosporins. The importance of the
characteristic antimicrobial suscepti-
bility pattern (cefotaxime- or ceftriax-
one-resistant, ceftazidime-susceptible)
may not be appreciated and may be
lost in the edited report. We paid spe-
cial attention to these isolates because
we were evaluating a VITEK 2 at the
time and noted the original suscepti-
bility pattern while reviewing the
machine reports. 
Multiplex PCR for plasmid-medi-
ated AmpC genes was performed on
strains EU4855 and EB9505 by using
the method described by Perez-Perez
and Hanson (8). Amplified products
of  ≈460 bp were produced which,
when sequenced, were identical to the
gene sequences encoding C-1 molec-
ular subgroup plasmid-mediated
AmpC enzymes CMY-2 (accession
no. X91840.1), and LAT-3 (accession
no. U77414.1) (9). This family of
enzymes is thought to be derived from
the chromosomal β-lactamase of C.
freundii and includes some of the
most widely distributed plasmid-
mediated AmpC β-lactamases. CMY-
2 has been recently found in E. coli
strains from Malaysia, which shares a
common border with Singapore (10). 
Although identifying these en-
zymes has little impact on managing
a patient, recognizing CTX-M and
plasmid-mediated AmpC enzymes
affects antimicrobial drug-resistant
surveillance because important new
mechanisms of extended-spectrum
cephalosporin resistance are repre-
sented. 
The following sequences have
been submitted to GenBank: EU17113
(accession no. AY517474), EU2673
(accession no. AY517476), EU2657
(accession no. AY517475), EU4855
(accession no. AY517473), and
EB9505 (accession no. AY514304).
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Table. Characteristics of isolates containing CTX-M and plasmid-mediated AmpC β-lactamases 
MIC (µg/mL)
a 
Isolate   Species  CAZ  FEP  CRO  AZT  pI
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